AbbVie (ABBV) Declares $0.64 Quarterly Dividend; 3.1% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Speculative Bullish Options Flow in AbbVie (ABBV) as Management Presents at Healthcare Conference -Susquehanna
September 12, 2017 2:33 PM EDTSusquehanna options strategist Alison Edwards notes speculative bullish options flow in AbbVie (NYSE: ABBV), with management presenting at a healthcare conference, as an investor sold 2k Nov 85/92.5 call spreads at $4.78 (getting long the 92.5 strike options), possibly a buyer of 2,500 Jan 95 Calls for $1.50, while... More
AbbVie (ABBV) Reports Upadacitinib (ABT-494) Meets All Primary & Ranked Secondary Endpoints in Second Phase 3 Study
September 11, 2017 8:03 AM EDTAbbVie (NYSE: ABBV) today announced positive top-line results from the Phase 3 SELECT-BEYOND clinical trial evaluating upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in patients with moderate to severe rheumatoid arthritis (RA) who did not adequately respond or were intolerant to treatment with biologic DMARDs (bDMARDs).1 Results showed that after 12 weeks of treatment, both once-daily doses of upadacitinib (15 mg and 30 mg) met the study's primary endpoints of ACR20* and low disease activity (LDA)**.1 All ranked secondary endpoints were also achieved with both doses.1 Upadacitinib is not... More
